Organon Acquires Dermavant Sciences (VTAMA tapinarof cream, 1%)

Avista Healthcare Partners and Damier Group Acquire sanotact Group GmbH

May 22, 2026

Healthcare Services

Avista Healthcare Partners (with strategic co-investor Damier Group) signed a definitive agreement to acquire Germany-based vitamins, minerals and supplements (VMS) platform sanotact Group GmbH. The deal also includes reinvestment by existing investor FLOTTE Beteiligungen GmbH, and expands Avista’s consumer healthcare exposure across manufacturing (CDMO) and branded supplement offerings.

Sun Pharma to Acquire Organon in $11.75 Billion All-Cash Deal

April 26, 2026

Healthcare Services

Sun Pharmaceutical Industries (Sun Pharma) entered into a definitive agreement to acquire all outstanding shares of Organon for $14.00 per share in an all-cash transaction valuing Organon at an enterprise value of $11.75 billion. The deal is expected to close in early 2027, subject to customary regulatory approvals and Organon stockholder approval.

Organon Acquires U.S. Rights to TOFIDENCE (tocilizumab-bavi) from Biogen

April 1, 2025

Pharmaceuticals

Organon has acquired regulatory and commercial rights in the United States for TOFIDENCE (tocilizumab-bavi), a biosimilar to Actemra, from Biogen. The deal includes an upfront payment to Biogen and Organon will assume tiered royalty and milestone obligations while Bio‑Thera Solutions will retain manufacturing rights for the U.S. market.

Roche Buys Telavant Holdings (Roivant/Pfizer) for $7.1B+

October 26, 2023

Healthcare Services

Roche entered into a definitive agreement to acquire Telavant Holdings, a company jointly owned by Roivant and Pfizer, for an upfront purchase price of $7.1 billion plus a near-term $150 million milestone payment. The deal gives Roche full rights to further develop, manufacture, and commercialize Telavant’s TL1A-directed antibody RVT-3101 in the US and Japan, with Pfizer retaining commercialization rights outside those territories.

NovaBay Pharmaceuticals Acquires DERMAdoctor

September 28, 2021

Consumer Products

NovaBay Pharmaceuticals, Inc. has entered into a definitive agreement to acquire DERMAdoctor, LLC for $15.0 million ( $12.0 million cash at closing plus up to $3.0 million in earnouts). The deal brings DERMAdoctor's ~30-product skincare portfolio and its 13-person team (co-founders Audrey and Jeff Kunin to remain) into NovaBay's commercial platform to expand its presence in the U.S. beauty market and capture revenue and operating synergies.

DermBiont Acquires SeylanMED to Expand Dermatology Pipeline

October 21, 2020

Biotechnology

DermBiont, a Boston-based clinical-stage precision dermatology company, has acquired SeylanMED, adding a targeted topical AKT inhibitor gel candidate for seborrheic keratosis to its pipeline. The acquisition expands DermBiont's therapeutic modalities and accelerates its objective to develop targeted topical treatments and live bacterial therapeutics for skin diseases.